狼疮低疾病活动状态(LLDAS)达标可区分系统性红斑狼疮试验中的应答者:阿尼鲁单抗IIb期MUSE试验的事后分析
该事后分析基于IIb期随机对照试验MUSE(NCT01438489),评估LLDAS作为SLE试验终点的可行性,并比较阿尼鲁单抗与安慰剂对LLDAS达标的影响。结果显示第52周LLDAS达标与SRI(4)和BICLA应答相关,阿尼鲁单抗300 mg组LLDAS达标率高于安慰剂组,作者认为LLDAS是临床有意义的SLE结局指标并支持其作为试验终点。
要点
- 第52周LLDAS达标与SRI(4)和BICLA应答相关(两者名义p<0.001)。
- 仅47%的SRI(4)应答者和51%的BICLA应答者达到LLDAS。
- 阿尼鲁单抗300 mg组第52周LLDAS达标率39%,高于安慰剂组17%(OR 3.41)。
核心结论
- LLDAS达标是临床有意义的SLE结局指标,阿尼鲁单抗较安慰剂使更多患者达到LLDAS标准,这些数据支持LLDAS作为SLE随机对照试验的终点。
研究设计与样本
- MUSE(NCT01438489)IIb期随机对照试验的事后分析,患者接受静脉安慰剂(n=102)或阿尼鲁单抗300 mg(n=99)、1000 mg(n=104),每4周一次加标准治疗共48周。
主要发现
- 第52周LLDAS达标与SRI(4)和BICLA相关:LLDAS达标者中74/85(87%)为SRI(4)应答者、62/84(74%)为BICLA应答者(两者名义p<0.001)。
- 仅74/159(47%)的SRI(4)应答者和62/121(51%)的BICLA应答者达到LLDAS。
- 阿尼鲁单抗治疗患者更早达到LLDAS,且更多患者至少一半观察时间处于LLDAS:300 mg组OR 3.04(95%CI 1.34至6.92,名义p=0.008),1000 mg组OR 2.17(95%CI 0.93至5.03,名义p=0.072),均对比安慰剂组。
- 第52周LLDAS达标率:安慰剂组17/102(17%),阿尼鲁单抗300 mg组39/99(39%),1000 mg组29/104(28%);300 mg组OR 3.41(95%CI 1.73至6.76,p<0.001),1000 mg组OR 2.03(95%CI 1.01至4.07,名义p=0.046),均对比安慰剂组。
关键数值与推荐
- LLDAS定义:SLE疾病活动指数2000≤4且无主要器官活动、无新发疾病活动、医师总体评估≤1、泼尼松龙≤7.5 mg/d且耐受标准免疫抑制剂剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (RCT) (MUSE [NCT01438489]) and then utilize LLDAS to discriminate between anifrolumab and placebo. METHODS: Patients received intravenous placebo (n=102) or anifrolumab (300 mg, n=99; 1,000 mg, n=104) Q4W plus standard of care for 48 weeks. LLDAS attainment (SLE Disease Activity Index 2000 ≤4 without major organ activity, no new disease activity, Physician's Global Assessment ≤1, prednisolone ≤7.5 mg/d and standard immunosuppressant dosage tolerance) was assessed. Associations with endpoints and LLDAS attainment differences between treatments were explored. RESULTS: LLDAS attainment at Week 52 was associated with SLE Responder Index 4 (SRI[4]) and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) (74/85[87%] and 62/84[74%] were also SRI[4] and BICLA responders, respectively; both nominal p<0.001). Only 74/159 (47%) of SRI(4) and 62/121 (51%) of BICLA responders reached LLDAS.Anifrolumab-treated patients achieved earlier LLDAS, and more spent at least half their observed time in LLDAS (OR vs. placebo; 300 mg: 3.04, 95% CI 1.34 to 6.92, nominal p=0.008; 1,000 mg: 2.17, 95% CI 0.93 to 5.03, nominal p=0.072) vs placebo-treated patients. At Week 52, 17/102 (17%), 39/99 (39%) and 29/104 (28%) of patients on placebo, anifrolumab 300 and 1,000 mg, respectively, attained LLDAS (OR vs. placebo; 300 mg: 3.41, 95% CI 1.73 to 6.76, p<0.001; 1,000 mg: 2.03, 95% CI 1.01 to 4.07, nominal p=0.046). CONCLUSIONS: LLDAS attainment represents a clinically meaningful SLE outcome measure, and anifrolumab is associated with more patients who met LLDAS criteria versus placebo. These data support LLDAS as an SLE RCT endpoint. TRIAL REGISTRATION NUMBER: NCT1438489; Post-results.
引用
- Morand EF, Trasieva T, Berglind A, et al. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018. PMID: 29420200. doi:10.1136/annrheumdis-2017-212504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。